Please assess the completion status of the following clinical trial:

Trial Title: Autologous Adipose Tissue Derived Mesenchymal Stem Cells Transplantation in Patient With Buerger's Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects who understand and sign the consent form for this study.~* Age :20-80, males and females~* Patients at least 6 months after Buerger's disease~* Patients with a luminal stenosis of more than 50% on angiography~* Rutherford class II-4, III-5 or III-6~* Subjects not eligible to undergo a revascularization or vascular bypass graft~* Patients who can't treat with traditional medication and need a arthroplasty.~* Patients whose lesion is 2\~6 cm2 in size~* Duration of pain over Grade 4(11-point numeric scale) : \> 4 months~Exclusion Criteria:~* Subjects who cannot survive more than 6 months with critical other complications.~* Patient with well-known active malignant tumor.~* Patients who exceed normal reference values from following test : PAP smear screening, chest X-ray, PSA, mammogram, occult blood test~* Patients in need of a immediate amputation and have a potentially life-threatening complications of critical ischemia~* Patients with uncontrolled iliac artery obstruction of targeted areas.~* Condition with targeted lower limb that have widespread necrosis or in need of amputation.~* End-stage renal failure patients who depend on hemodialysis~* Patients with uncontrolled diabetes mellitus (HbA1c \> 10%).~* Treatment with immunosuppressant (prednisone \> 5mg/day).~* Treatment with a anti-inflammatory drugs within 1 weeks prior to enrollment.~* Women who are pregnant or breast feeding or planning to become pregnant during the study.~* Subjects who have cerebrovascular accident within 6 months prior to inclusion in the study.~* Patients with acute myocardial infarction, angina pectoris.~* Subjects who had been underwent a cardiovascular surgery such as carotid endarterectomy, arterial aneurysm, bypass surgery and coronary bypass surgery within 3 months prior to inclusion in the study.~* Participation in another clinical trial or treatment with a different investigational product within 3 months prior to inclusion in the study.~* Other pathologic conditions or circumstances that difficult participation in the study according to medical criteria

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- RNL-Vascostem® (Type: EXPERIMENTAL): drug name and ingredients : RNL-Vascostem\[Autologous adipose tissue derived mesenchymal stem cells\] dosage : Intramuscular infusion, 5 x 10e6 cells/kg

Based on this trial design, predict the completion outcome and termination type (if applicable).